<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325961</url>
  </required_header>
  <id_info>
    <org_study_id>BRD 10/12-O</org_study_id>
    <nct_id>NCT01325961</nct_id>
  </id_info>
  <brief_title>Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal Cancers</brief_title>
  <acronym>RCMI PELVIS</acronym>
  <official_title>Medico-economic Evaluation Comparing Conformal Radiotherapy With Intensity Modulation (IMRT) Performed by, Helical Tomotherapy (Hi Art) and Dynamic Arc Therapy (RapidArc, VMAT) in Cancers With Pelvic Lymph Node Irradiation (Prostate, Cervix, Anal Canal)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is a medico-economic evaluation to estimate a cost differential between&#xD;
      three modalities of Intensity-Modulated Radiation Therapy for cancers of the prostate, cervix&#xD;
      and anal canal with pelvic lymph node irradiation : treatment with helical Tomotherapy and&#xD;
      dynamic arc therapy using two different technologies: RapidArc or VMAT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2011</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Medico-economic study : medical cost differential between 3 ways of Radiotherapy by IMRT (helical tomotherapy and dynamic arc therapy : RapidArc and VMAT).</measure>
    <time_frame>2 months</time_frame>
    <description>Costs of the devices, maintenance costs ; personnel costs directly related to the medical therapeutic procedure (physicians, medical physicists, dosimetry, technicians).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Others economic criteria</measure>
    <time_frame>2 months</time_frame>
    <description>the estimation of the cost differential by individualizing the preparation phase and phase radiation&#xD;
the analysis of the possible impact of learning in helical tomotherapy and dynamic arc therapy with VMAT and RapidArc measured on direct costs (depending on the age of implantation and equipment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical response and safety of the treatment by radiotherapy</measure>
    <time_frame>18 Months (cervix and canal anal) or 36 months (prostate)</time_frame>
    <description>Assess the skin and mucosal toxicity (acute, delayed) : CTCAEv3&#xD;
Assess the prognostic factors of onset of toxicity&#xD;
Assess oncological results</description>
  </secondary_outcome>
  <enrollment type="Actual">217</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Anal Canal Cancers</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  WHO performance index ≤ 2&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  histologically proven carcinoma: Anal canal cancer locally advanced (&gt; 4 cm and / or&#xD;
             N1 to N3) under irradiation on pelvic and inguinal lymph nodes with concurrent&#xD;
             chemotherapy. The boost with brachytherapy are accepted Prostate cancer with pelvic&#xD;
             lymph nodes and radiation or hormone therapy Cervical Cancer under a purely medical&#xD;
             treatment involving irradiation on pelvic lymph nodes and primary tumor with&#xD;
             concurrent chemotherapy without surgery. The Boost by external radiotherapy or&#xD;
             brachytherapy are accepted.&#xD;
&#xD;
          -  The investigator must ensure that the patient has not expressed its opposition to&#xD;
             participate in this study. The signing of a consent form is optional;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of invasive cancer other than basal cell carcinomas.&#xD;
&#xD;
          -  Indication of re-irradiation&#xD;
&#xD;
          -  para-aortic radiotherapy associated with pelvic irradiation.&#xD;
&#xD;
          -  post-operative radiotherapy.&#xD;
&#xD;
          -  geographical distance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance publique des Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Clinique Claude Bernard</name>
      <address>
        <city>Metz</city>
        <zip>57 070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Oncorad</name>
      <address>
        <city>Montauban</city>
        <zip>82000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Oncorad</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>March 28, 2011</study_first_submitted>
  <study_first_submitted_qc>March 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2011</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate, cervical and anal canal cancers with pelvic lymph node irradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

